PriceTargets.com logo

Gyre Therapeutics - GYRE Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $17.00
  • Forecasted Upside: 115.19%
  • Number of Analysts: 5
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$7.90 As of 12/4/2025 05:00 PM ET
▲ +0.26 (3.40%)

This chart shows the closing price for GYRE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Gyre Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GYRE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GYRE

Analyst Price Target is $17.00
▲ +115.19% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Gyre Therapeutics in the last 3 months. The average price target is $17.00, with a high forecast of $18.00 and a low forecast of $16.00. The average price target represents a 115.19% upside from the last price of $7.90.

This chart shows the closing price for GYRE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 5 contributing investment analysts is to hold stock in Gyre Therapeutics. This rating has held steady since September 2025, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 2 sell ratings
Ratings as of
11/4/2025
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/14/2025Zacks ResearchUpgradeStrong Sell ➝ Hold
10/16/2025Zacks ResearchDowngradeHold ➝ Strong Sell
10/10/2025Jefferies Financial GroupInitiated CoverageBuy$16.00
10/10/2025Jefferies Financial GroupInitiated CoverageBuy$16.00
10/8/2025Weiss RatingsReiterated RatingSell (D) ➝ Sell (D)
9/27/2025Weiss RatingsReiterated RatingSell (D) ➝ Sell (D)
8/26/2025HC WainwrightInitiated CoverageBuy$18.00
3/11/2025Noble FinancialInitiated CoverageOutperform
(Data available from 12/5/2020 forward)

News Sentiment Rating

0.83 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
5/8/2025
  • 7 very positive mentions
  • 18 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/7/2025
  • 1 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2025
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2025
  • 3 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/5/2025
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 4 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2025
  • 5 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2025

Current Sentiment

  • 5 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Gyre Therapeutics logo
Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $7.90
Low: $7.50
High: $7.90

50 Day Range

MA: $7.77
Low: $7.15
High: $8.87

52 Week Range

Now: $7.90
Low: $6.11
High: $14.42

Volume

45,891 shs

Average Volume

52,318 shs

Market Capitalization

$761.01 million

P/E Ratio

263.42

Dividend Yield

N/A

Beta

1.96

Frequently Asked Questions

What sell-side analysts currently cover shares of Gyre Therapeutics?

The following Wall Street analysts have issued reports on Gyre Therapeutics in the last year: HC Wainwright, Jefferies Financial Group Inc., Noble Financial, Wall Street Zen, Weiss Ratings, and Zacks Research.
View the latest analyst ratings for GYRE.

What is the current price target for Gyre Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Gyre Therapeutics in the last year. Their average twelve-month price target is $17.00, suggesting a possible upside of 115.2%. HC Wainwright has the highest price target set, predicting GYRE will reach $18.00 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $16.00 for Gyre Therapeutics in the next year.
View the latest price targets for GYRE.

What is the current consensus analyst rating for Gyre Therapeutics?

Gyre Therapeutics currently has 1 sell rating, 1 hold rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in GYRE, but not buy more shares or sell existing shares.
View the latest ratings for GYRE.

What other companies compete with Gyre Therapeutics?

Other companies that are similar to Gyre Therapeutics include Dyne Therapeutics, MorphoSys, Adaptive Biotechnologies, Catalyst Pharmaceuticals and Arcus Biosciences. Learn More about companies similar to Gyre Therapeutics.

How do I contact Gyre Therapeutics' investor relations team?

Gyre Therapeutics' physical mailing address is 611 GATEWAY BLVD. SUITE 710, SOUTH SAN FRANCISCO CA, 94080. The company's listed phone number is (619) 949-3681 and its investor relations email address is [email protected]. The official website for Gyre Therapeutics is www.catalystbiosciences.com. Learn More about contacing Gyre Therapeutics investor relations.